Supplementary Figure 1

Normal mucosa (Original, x 400)



Colorectal cancer (Original, x 400)



Ulcerative colitis (Original, x 400)



Ulcerative colitis (original, x 1000)



Supplementary Figure 2
Apoptotic rates



Supplementary Figure 3-1



Supplementary Figure 3-2



Supplementary Figure 4

A

Control | Day 56 | Day 67 | Day 67, Et



B

Control | Day 56 | Day 67 | Day 67, Et



Supplementary Figure 1.

TNF-α protein expression in human colon tissues. Human colon tissues were immunostained with anti-human TNF-α antibody as described in Methods. Representative results from 4 patients with ulcerative colitis and from 3 patients with advanced colorectal cancer are shown here. Boxed areas are shown at higher magnification in the lower right panel. Similar results were obtained from each group and representative results are shown here. Original magnification, x 400; inset, x 1000.

Supplementary Figure 2

Apoptotic cell numbers in WT and TNF-Rp55$^{-/-}$ mice. Colon tissues were obtained at the indicated time-points and subjected to TUNEL staining as described in Methods. TUNEL-positive cell numbers were determined on 5 randomly chosen visual fields at x 400 magnification. Values represent mean + SD, *, $p<0.05$ vs. untreated mice. Similar results were obtained from 3 independent experiments and representative results are shown here.

Supplementary Figure 3.

Immunohistochemical identification of infiltrating cells. Colons were removed from WT mice (upper panels) and TNF-Rp55$^{-/-}$ mice (lower panels) at days 0, 7, and 56, and processed for immunohistochemical analysis for myeloperoxidase, F4/80, CD4, CD8, or DEC205, as described in Methods. Representative results from 5 independent animals are shown here. Original magnification, x 400.

Supplementary Figure 4.

The effects of a TNF antagonist, Etanercept, on granulocyte and macrophage infiltration in colon carcinogenesis. Colons were obtained at days 56 and 67 and immunostained with anti-myeloperoxidase (A) or anti-F4/80 antibodies (B), as described in Methods. Representative results from 5 independent animals are shown here. Original maginification, x 400.

Supplementary Table 1.

β-catenin status in Etanercept untreated and Etanercept treated mice

Treatment	**Sample**	**Detected β-Catenin mutations**
Etanercept untreated	1	codon 37 (TCT → CCT)
	2	codon 16 (CCG → TCG)
	3	codon 17 (GAC → GGC)
	4	codon 34 (GGA → GAA)
	5	codon 33 (TCT → TTT)
	6	codon 58 (GAC → GGC)
	7	codon 71 (TCC → TC)
	8	codon 17 (GAC → GGC)
	9	codon 19 (AAA → AAG)
	10	codon 37 (TCT →CCT)
Etanercept treated	1	codon 27 (CAG → CGG)
	2	not detected
	3	codon 34 (GGA →GAA)
	4	not detected
	5	codon 16 (CCG → TCG)
	6	not detected
	7	not detected
	8	not detected
	9	not detected
	10	not detected